121 related articles for article (PubMed ID: 11131451)
1. Transjugular intrahepatic portosystemic shunt (TIPS) augments hyperinsulinemia in patients with cirrhosis.
Kaser S; Föger B; Waldenberger P; Nachbaur K; Propst A; Jaschke W; Vogel W; Patsch JR
J Hepatol; 2000 Dec; 33(6):902-6. PubMed ID: 11131451
[TBL] [Abstract][Full Text] [Related]
2. Effect of transjugular intrahepatic portosystemic shunt on glycometabolism in cirrhosis patients.
Su AP; Cao SS; Le Tian B; Da Zhang Z; Hu WM; Zhang Y; Wang ZL; Babu SR; Hu T
Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):53-9. PubMed ID: 22099870
[TBL] [Abstract][Full Text] [Related]
3. Fasting hyperglucagonemia in patients with transjugular intrahepatic portosystemic shunts (TIPS).
Raddatz D; Rossbach C; Buchwald A; Scholz KH; Ramadori G; Nolte W
Exp Clin Endocrinol Diabetes; 2005 May; 113(5):268-74. PubMed ID: 15926112
[TBL] [Abstract][Full Text] [Related]
4. Insulin sensitivity and body composition in cirrhosis: changes after TIPS.
Holland-Fischer P; Nielsen MF; Vilstrup H; Tønner-Nielsen D; Mengel A; Schmitz O; Grønbaek H
Am J Physiol Gastrointest Liver Physiol; 2010 Aug; 299(2):G486-93. PubMed ID: 20489042
[TBL] [Abstract][Full Text] [Related]
5. [Effect of transjugular portosystemic shunt on insulin resistance].
Stefánková J; Safka V; Fejfar T; Hůlek P; Dresslerová I; Krajina A
Vnitr Lek; 2002 Nov; 48(11):1017-24. PubMed ID: 12577452
[TBL] [Abstract][Full Text] [Related]
6. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.
Chalasani N; Gorski JC; Patel NH; Hall SD; Galinsky RE
Hepatology; 2001 Dec; 34(6):1103-8. PubMed ID: 11731998
[TBL] [Abstract][Full Text] [Related]
7. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
[TBL] [Abstract][Full Text] [Related]
8. The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS).
Benten D; Schulze zur Wiesch J; Sydow K; Koops A; Buggisch P; Böger RH; Gaydos CA; Won H; Franco V; Lohse AW; Ray SC; Balagopal A
BMC Gastroenterol; 2011 Oct; 11():107. PubMed ID: 21978390
[TBL] [Abstract][Full Text] [Related]
9. Increase of serum estradiol in cirrhotic men treated by transjugular intrahepatic portosystemic stent shunt.
Nolte W; Schindler CG; Figulla HR; Wuttke W; Hüfner M; Hartmann H; Ramadori G
J Hepatol; 2001 Jun; 34(6):818-24. PubMed ID: 11451164
[TBL] [Abstract][Full Text] [Related]
10. Quantification of intrahepatic portosystemic shunting after placement of a transjugular intrahepatic portosystemic shunt.
Walser EM; Harris VM; Harman JT; Park HM; Siddiqui AR
J Vasc Interv Radiol; 1996; 7(2):263-7. PubMed ID: 9007808
[TBL] [Abstract][Full Text] [Related]
11. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.
Deschênes M; Dufresne MP; Bui B; Fenyves D; Spahr L; Roy L; Lafortune M; Pomier-Layrargues G
Am J Gastroenterol; 1999 May; 94(5):1361-5. PubMed ID: 10235219
[TBL] [Abstract][Full Text] [Related]
12. Brain regional homogeneity changes following transjugular intrahepatic portosystemic shunt in cirrhotic patients support cerebral adaptability theory--a resting-state functional MRI study.
Ni L; Qi R; Zhang LJ; Zhong J; Zheng G; Wu X; Fan X; Lu GM
Eur J Radiol; 2014 Mar; 83(3):578-83. PubMed ID: 24299611
[TBL] [Abstract][Full Text] [Related]
13. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt.
Rabie RN; Cazzaniga M; Salerno F; Wong F
Am J Gastroenterol; 2009 Oct; 104(10):2458-66. PubMed ID: 19532126
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion.
Tan HK; James PD; Sniderman KW; Wong F
J Gastroenterol Hepatol; 2015 Feb; 30(2):389-95. PubMed ID: 25168607
[TBL] [Abstract][Full Text] [Related]
15. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
Berres ML; Lehmann J; Jansen C; Görtzen J; Meyer C; Thomas D; Zimmermann HW; Kroy D; Schumacher F; Strassburg CP; Sauerbruch T; Trautwein C; Wasmuth HE; Trebicka J
Liver Int; 2016 Mar; 36(3):386-94. PubMed ID: 26212075
[TBL] [Abstract][Full Text] [Related]
16. Transjugular intrahepatic portosystemic shunt for treatment of bleeding ectopic varices with portal hypertension.
Shibata D; Brophy DP; Gordon FD; Anastopoulos HT; Sentovich SM; Bleday R
Dis Colon Rectum; 1999 Dec; 42(12):1581-5. PubMed ID: 10613477
[TBL] [Abstract][Full Text] [Related]
17. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
[TBL] [Abstract][Full Text] [Related]
18. Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis.
Busk TM; Bendtsen F; Poulsen JH; Clemmesen JO; Larsen FS; Goetze JP; Iversen JS; Jensen MT; Møgelvang R; Pedersen EB; Bech JN; Møller S
Am J Physiol Gastrointest Liver Physiol; 2018 Feb; 314(2):G275-G286. PubMed ID: 29074483
[TBL] [Abstract][Full Text] [Related]
19. Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis.
Karasu Z; Gurakar A; Kerwin B; Hulagu S; Jazzar A; McFadden R; Nour B; Sebastian A; Cassidy F; Stokes K; Van Thiel DH; Wright H
Dig Dis Sci; 2000 Oct; 45(10):1971-6. PubMed ID: 11117569
[TBL] [Abstract][Full Text] [Related]
20. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
Ginès P; Uriz J; Calahorra B; Garcia-Tsao G; Kamath PS; Del Arbol LR; Planas R; Bosch J; Arroyo V; Rodés J
Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
